Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Amgen (NQ: AMGN )

265.52 +1.25 (+0.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
1 Spectacular Dividend Stock Every Investor Should Consider
This biotech pioneer has been an exceptional growth and income stock. 
Via The Motley Fool
Why NASDAQ:AMGN is a Top Pick for Dividend Investors.
Why AMGEN INC (NASDAQ:AMGN) qualifies as a good dividend investing stock. 
Via Chartmill
Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors
Via Benzinga
P/E Ratio Insights for Amgen
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
Don't give up on these stocks too fast. 
Via The Motley Fool
20 Analysts Have This to Say About Amgen
Via Benzinga
Amgen's Rare Autoimmune Disease Candidate Shows Improvement In Disease Burden In Treating Sjögren's Syndrome
Amgen Inc (NASDAQ: AMGN) released new  
Via Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
Amgen Wins Big With FDA, Analyst Sees Soaring Potential
The FDA approval of Amgen, Inc’s (NASDAQ: AMGN) biosimilar version of Johnson & Johnson's (NYSE: JNJ) psoriasis treatment, Stelara, for multiple inflammatory diseases sent 
Via Benzinga
Exposures Product Safety
Earnings Outlook For Amgen
Via Benzinga
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Performance Comparison: Amgen And Competitors In Biotechnology Industry
Via Benzinga
These Analysts Revise Their Forecasts On Amgen After Q3 Results
Amgen Inc (NASDAQ: AMGN) reported mixed third-quarter financial results. 
Via Benzinga
5 Dow stocks to track during the market correction
The Dow Jones Industrial Average is struggling in correction territory, but savvy investors keep an eye on resilient stocks like Microsoft, Amgen, and Walmart. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END 
Via FinancialNewsMedia
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
Fear & Greed Index Remains In 'Fear' Zone Ahead Of Fed's Decision
The CNN Money Fear and Greed index remained in the "Fear" zone on Tuesday. U.S. stocks closed higher on Tuesday, ahead of the Federal Reserve's monetary policy decision. The central bank is widely... 
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Treasury Announcement More Important Than Fed's, Japan Abandons Yield Control, Tesla Under $200
To gain an edge, this is what you need to know today. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Amgen Lifts Annual Outlook After Q3 Performance, But Stock Still Falls - Here's Why
Amgen Inc (NASDAQ: AMGN) reported Q3 FY23 sales of $6.90 billion, slightly missin 
Via Benzinga
Amgen Boosts Outlook Following Horizon Takeover, But Dips On Light Enbrel Sales
The company just finished its acquisition of Horizon Therapeutics this month. 
Via Investor's Business Daily
U.S. Stocks Poised To Extend Gains As Fed Meeting Gets Underway; Why This Analyst Expects 'Young Bull Market' To Remain Alive
US stocks are priming for a modestly higher open on Tuesday as traders look to another slew of earnings and the Fed decision. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
2 Dow Jones Dividend Stocks to Buy Hand Over Fist Right Now
These two defensive dividend stocks sport compelling valuations and attractive yields. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Microsoft Leads These 5 Dow Jones Stocks Near Buy Points
Microsoft, one of just two Magnificent Seven stocks to move higher last week, leads this watchlist of five Dow Jones stocks. near buy points. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Bears Roam Wall Street As Middle East Conflict, Earnings Outlook Raise Concerns Despite Strong Q3 US Economic Growth: This Week In Markets
It has been another week of volatility in the stock market, characterized by mounting fears of a wider Middle East conflict and a more cautious fourth-quarter earnings outlook announced by U.S.... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.